CDKN2A testing for malignant melanoma
Record ID 32010001394
English
Authors' recommendations:
Cutaneous malignant melanoma (CMM) is an invasive skin cancer that originates from the pigmentproducing skin cells known as melanocytes. CMM is the most lethal form of skin cancer, causing more than 8000 deaths in the United States annually. Risk factors for development of CMM include: exposure to sunlight, particularly sunburns during childhood; family history of melanoma or pancreatic cancer; fair skin and/or red or blonde hair; and a large number of freckles or moles. The first sign of CMM is often a mole that changes color or shape. Approximately 10% of patients diagnosed with CMM report a family history of the disease. Genetic studies have identified a gene known as the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene, which is altered in approximately 40% of CMM patients with a family history of melanoma. The CDKN2A gene is transmitted in an autosomal dominant fashion, with variable expressivity and incomplete penetrance. Current treatment for CMM includes surgical excision of the lesion, potentially followed by chemotherapy, radiation therapy, and/or immunotherapy. CMM has a good clinical prognosis if detected at an early stage.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=8479
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Cyclin-Dependent Kinase 2
- Melanoma
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.